Prevention of Recurrent Spontaneous Preterm Delivery Using Probiotics (Clostridium butyricum, Enterococcus faecium, and Bacillus subtilis; PPP Trial): Protocol for a Prospective, Single-Arm, Nonblinded, Multicenter Trial (Preprint)
Preprint
- 26 April 2024
- preprint
- Published by JMIR Publications Inc. in JMIR Preprints
Abstract
BACKGROUND The rate of recurrent spontaneous preterm delivery (sPTD) ranges between 27% and 34% and is 22.3% in Japan. Although it currently remains unclear whether probiotics prevent sPTD, retrospective studies recently reported a reduction in the rate of recurrent sPTD with the administration of probiotics including Clostridium spp., which induce regulatory T cells that play an important role in maintaining pregnancy. OBJECTIVE The objective of this trial is to evaluate the preventative effects of available oral probiotics, including Clostridium butyricum, on recurrent sPTD. METHODS This is a prospective, single-arm, nonblinded, multicenter trial in Japan. The sample size required for this trial is 345 pregnant women with a history of sPTD, considering a clinically significant reduction in the relative risk of 30% (risk ratio=0.7). The primary endpoint is the rate of recurrent sPTD at <37 weeks of gestation. The secondary endpoints are the rate of sPTD at <34 weeks of gestation, the rate of recurrent sPTD at <28 weeks of gestation, the ratio of intestinal Clostridium spp. (detected by next-generation sequencing), and bacterial vaginosis (using the Nugent score). RESULTS The trial procedures were approved by the Clinical Research Review Board of Toyama University Hospital (SCR2020008) on March 31, 2021. The trial was registered on the Japan Registry of Clinical Trial website on April 28, 2021. Recruitment began on May 1, 2021, and the trial is estimated to finish on March 31, 2025. CONCLUSIONS The findings will clarify the rate of recurrent sPTD following probiotic administration including Clostridium butyricum. Outcomes from this trial will inform clinical practice and guide future randomized controlled trials. CLINICALTRIAL Japan Registry of Clinical Trials jRCTs041210014; https://jrct.niph.go.jp/latest-detail/jRCTs041210014 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/59928Keywords
All Related Versions
- Published version: JMIR Research Protocols, 13 (1), e59928.
This publication has 29 references indexed in Scilit:
- National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysisThe Lancet, 2023
- Global, regional, and national causes of under-5 mortality in 2000–19: an updated systematic analysis with implications for the Sustainable Development GoalsThe Lancet Child & Adolescent Health, 2022
- Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysisThe Lancet Global Health, 2019
- The epidemiology, etiology, and costs of preterm birthSeminars in Fetal and Neonatal Medicine, 2016
- Recurrence of stillbirth and second trimester pregnancy lossAmerican Journal of Medical Genetics Part A, 2016
- Helios-positive functional regulatory T cells are decreased in decidua of miscarriage cases with normal fetal chromosomal contentJournal of Reproductive Immunology, 2015
- Epidemiology and causes of preterm birthThe Lancet, 2008
- Probiotics for preventing preterm labour2006
- Regulatory T cells mediate maternal tolerance to the fetusNature Immunology, 2004
- A constipation scoring system to simplify evaluation and management of constipated patientsDiseases of the Colon & Rectum, 1996